Healthcare provider profile · identity verified

Michael Rhea King, MD

Family Practice · LUTZ, FL · NPI 1578591095

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	380	153
Amlodipine Besylate	Amlodipine Besylate	244	100
Lisinopril	Lisinopril	235	91
Metformin Hcl	Metformin Hcl	225	82
Levothyroxine Sodium	Levothyroxine Sodium	217	85
Losartan Potassium	Losartan Potassium	213	85
Gabapentin	Gabapentin	212	76
Rosuvastatin Calcium	Rosuvastatin Calcium	174	65
Omeprazole	Omeprazole	166	61
Metoprolol Tartrate	Metoprolol Tartrate	161	52
Simvastatin	Simvastatin	128	51
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	121	27
Furosemide	Furosemide	119	43
Tamsulosin Hcl	Tamsulosin Hcl	114	48
Pantoprazole Sodium	Pantoprazole Sodium	101	42
Metoprolol Succinate	Metoprolol Succinate	100	28
Hydrochlorothiazide	Hydrochlorothiazide	93	39
Albuterol Sulfate Hfa	Albuterol Sulfate	92	43
Carvedilol	Carvedilol	92	34
Montelukast Sodium	Montelukast Sodium	88	28
Tizanidine Hcl	Tizanidine Hcl	86	31
Alprazolam	Alprazolam	83	26
Fluticasone Propionate	Fluticasone Propionate	81	35
Meloxicam	Meloxicam	79	30
Sertraline Hcl	Sertraline Hcl	79	29
Trazodone Hcl	Trazodone Hcl	76	29
Duloxetine Hcl	Duloxetine Hcl	75	21
Famotidine	Famotidine	74	29
Glimepiride	Glimepiride	73	26
Eliquis	Apixaban	70	25
Clopidogrel	Clopidogrel Bisulfate	63	23
Escitalopram Oxalate	Escitalopram Oxalate	63	28
Baclofen	Baclofen	62	22
Jardiance	Empagliflozin	60	27
Triamcinolone Acetonide	Triamcinolone Acetonide	55	26
Potassium Chloride	Potassium Chloride	53	22
Pravastatin Sodium	Pravastatin Sodium	52	23
Tramadol Hcl	Tramadol Hcl	52	25
Alendronate Sodium	Alendronate Sodium	51	21
Finasteride	Finasteride	50	20
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	49	16
Atenolol	Atenolol	47	18
Methylprednisolone	Methylprednisolone	45	36
Donepezil Hcl	Donepezil Hcl	42	17
Ropinirole Hcl	Ropinirole Hcl	37	suppressed
Citalopram Hbr	Citalopram Hydrobromide	36	12
Pioglitazone Hcl	Pioglitazone Hcl	36	12
Quetiapine Fumarate	Quetiapine Fumarate	36	12
Prednisone	Prednisone	35	22
Azithromycin	Azithromycin	34	29
Diclofenac Sodium	Diclofenac Sodium	34	12
Mirtazapine	Mirtazapine	33	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	32	13
Synthroid	Levothyroxine Sodium	31	suppressed
Temazepam	Temazepam	29	11
Doxycycline Hyclate	Doxycycline Hyclate	28	15
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	26	suppressed
Sildenafil Citrate	Sildenafil Citrate	26	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	25	18
Hydroxyzine Hcl	Hydroxyzine Hcl	25	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	25	suppressed
Meclizine Hcl	Meclizine Hcl	25	suppressed
Buspirone Hcl	Buspirone Hcl	23	suppressed
Enalapril Maleate	Enalapril Maleate	23	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	22	suppressed
Calcitriol	Calcitriol	22	suppressed
Glipizide	Glipizide	22	suppressed
Memantine Hcl	Memantine Hcl	21	11
Nifedipine Er	Nifedipine	21	suppressed
Primidone	Primidone	21	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	20	suppressed
Bupropion Xl	Bupropion Hcl	20	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	20	11
Lantus	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Nystatin	Nystatin	20	14
Warfarin Sodium	Warfarin Sodium	20	suppressed
Allopurinol	Allopurinol	19	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	19	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	19	suppressed
Metformin Hcl Er	Metformin Hcl	19	suppressed
Pregabalin	Pregabalin	19	12
Sucralfate	Sucralfate	19	suppressed
Terazosin Hcl	Terazosin Hcl	19	suppressed
Celecoxib	Celecoxib	18	suppressed
Diazepam	Diazepam	18	suppressed
Farxiga	Dapagliflozin Propanediol	18	suppressed
Lorazepam	Lorazepam	18	11
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	17	suppressed
Ibandronate Sodium	Ibandronate Sodium	17	suppressed
Levetiracetam	Levetiracetam	17	suppressed
Xarelto	Rivaroxaban	17	suppressed
Tradjenta	Linagliptin	16	suppressed
Valsartan	Valsartan	16	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	15	14
Clonidine Hcl	Clonidine Hcl	15	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	15	suppressed
Ketoconazole	Ketoconazole	15	suppressed
Nitroglycerin	Nitroglycerin	15	11
Oxycodone Hcl	Oxycodone Hcl	15	suppressed
Spironolactone	Spironolactone	15	suppressed
Aripiprazole	Aripiprazole	14	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	14	suppressed
Bupropion Hcl Sr	Bupropion Hcl	13	suppressed
Fenofibrate	Fenofibrate	13	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	13	suppressed
Paroxetine Hcl	Paroxetine Hcl	13	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Digoxin	Digoxin	12	suppressed
Ibuprofen	Ibuprofen	12	suppressed
Insulin Aspart Flexpen	Insulin Aspart	12	suppressed
Pro Comfort Pen Needle	Pen Needle, Diabetic	12	suppressed
Terbinafine Hcl	Terbinafine Hcl	12	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	12	suppressed
Clonazepam	Clonazepam	11	suppressed
Methocarbamol	Methocarbamol	11	suppressed
Mupirocin	Mupirocin	11	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Ramipril	Ramipril	11	suppressed
Topiramate	Topiramate	11	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error